Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed
A Phase III Prospective Randomized Study of Adjuvant Chemotherapy With Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer With Companion Tumour Marker Evaluation
Sponsor: Cancer and Leukemia Group B
This PHASE3 trial investigates Lung Cancer and is currently completed. Cancer and Leukemia Group B leads this study, which shows 9 recorded versions since 1994 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — May 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 1994
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer and Leukemia Group B
- Eastern Cooperative Oncology Group
- NCIC Clinical Trials Group
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States, Ann Arbor, United States, Atlanta, United States, Baltimore, United States, Billings, United States, Biloxi, United States, Birmingham, United States, Boston, United States, Buffalo, United States, Calgary, Canada and 94 more location s